Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

Copaxone (glatiramer) is a prescription drug used to treat certain types of multiple sclerosis (MS). Copaxone’s cost may depend on factors such as your dosage, whether you have health insurance, and ...

Jul. 4—MORGANTOWN — The tangled world of generic pharmaceuticals took another twist last week, as Mylan Pharmaceuticals filed suit in federal court against Israel-based Teva, alleging Teva illegally ...

Johnson & Johnson’s Momenta Pharmaceuticals unit is crying patent infringement against Mylan—now Viatris—plus two of the generics maker’s Indian manufacturing partners, according to a new lawsuit. But ...

(Reuters) - The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The generic drug ...

The FDA approved the first generic version of Copaxone (glatiramer acetate injection) to treat patients with relapsing forms of multiple sclerosis (MS), giving a green light to the abbreviated new ...

In the late 1960s, three Weizmann Institute of Science researchers developed several protein-like molecules, called copolymers, that they believed would produce a disease similar to multiple sclerosis ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.